Clinical TrialsSearch results
Number of results: 778
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with RRMM
- Relapsed/Refractory Multiple Myeloma
- Kakinuma Yuki
- 2022-02-01
Recruiting
- Phase II trial of docetaxel/pembrolizumab in head and neck squamous cell carcinoma
- head and neck squamous cell carcinoma
- Shimizu Yasushi
- 2022-02-01
Recruiting
- A MULTICENTER, PLACEBO-CONTROLLED, RANDOMIZED, DOUBLE-BLIND PHASE III CLINICAL TRIAL OF OBINUTUZUMAB IN PATIENTS WITH ACTIVE LUPUS NEPHRITIS
- Lupus Nephritis
- Tanaka Yoshiya
- 2021-12-25
Recruiting
- Phase 3 Study of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)
- NSCLC Harboring HER2 Exon 19 or 20 Mutations
- Inoguchi Akihiro
- 2021-12-23
Not yet recruiting
- Clinical trial to verify safety and efficacy of Stemirac that does not meet in-process control specifications and shipping specifications for acute traumatic spinal cord injury patients.
- Traumatic Spinal Cord Injury
- Tomii Ryo
- 2021-12-18
Recruiting
- A Study of Macitentan in Japanese Pediatric Participants with Pulmonary Arterial Hypertension
- Pulmonary Arterial Hypertension
- Nakano Masayoshi
- 2021-12-18
Recruiting
- Cabozantinib ePRO study
- Renal cell carcinoma
- Osawa Takahiro
- 2021-12-06
Not yet recruiting
- Relationship between electromyography and force depending on joint angles.
- Healthy adult (Electromyography recording in the quadriceps)
- Sato Yoichiro
- 2021-11-27
Other
- Efficacy and safety of oral semaglutide 50 mg once daily in East Asian participants with overweight or obesity (NN9932-4738, OASIS 2)
- Obesity
- Hirose Ryoma
- 2021-11-26
Recruiting
- Anti-fibrotic effects of the IP receptor agonist
- pulmonary arterial hypertension associated with systemic sclerosis
- Atsumi Tatsuya
- 2021-11-26